Related Experiment Video
Updated: Jul 11, 2025
Clonogenic Assay: Adherent Cells
Published on: March 13, 2011
Abstract:
In a phase I trial of CMG901-a first-in-class antibody-drug conjugate targeting claudin 18.2-researchers found that it can best current therapies for treating gastric and gastroesophageal cancers. Historically, progression-free survival (PFS) hovers around 7 months and overall survival (OS) around 14 to 16 months. However, depending on the dose, PFS with CMG901 ranged from 3.3 to 14.5 months, and OS ranged from 8.5 months to not reached, after a median follow up of 6 months.
Insights
CMG901, a novel antibody-drug conjugate, shows promise in treating gastric and gastroesophageal cancers. This first-in-class therapy demonstrated improved progression-free survival and overall survival compared to current treatments.
Area of Science:
- Oncology
- Pharmacology
Background:
- Gastric and gastroesophageal cancers are significant health concerns with limited treatment options.
- Current therapies for these cancers have historically shown modest progression-free survival (PFS) and overall survival (OS).
Purpose of the Study:
- To evaluate the safety and efficacy of CMG901, a first-in-class antibody-drug conjugate targeting claudin 18.2.
- To compare the outcomes of CMG901 treatment with historical data for existing therapies.
Main Methods:
- Phase I clinical trial.
- Administration of CMG901, an antibody-drug conjugate targeting claudin 18.2.
- Assessment of progression-free survival (PFS) and overall survival (OS) at various doses.
Main Results:
- CMG901 demonstrated a wide range of PFS from 3.3 to 14.5 months and OS from 8.5 months to not reached.
- These results suggest potential superiority over historical PFS of approximately 7 months and OS of 14-16 months.
- Outcomes varied depending on the administered dose.
Conclusions:
- CMG901 represents a promising new therapeutic strategy for gastric and gastroesophageal cancers.
- The observed survival data indicate that CMG901 may offer improved outcomes compared to current standard treatments.
- Further investigation in larger trials is warranted to confirm these findings.
